ERGO / Entia Biosciences, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5

Entia Biosciences, Inc.
US ˙ OTCPK

Shares Outstanding 34,060,882 shares
Insider Shares23,395,854 shares
Insider Ownership68.69 %
Total Insiders10
Insider Sentiment Score

The Insider Sentiment Score finds the companies being bought by corporate insiders.

It is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of insider accumulation. The scoring model uses a combination of the net number of insiders buying the prior 90 days, the total shares bought as a percentage of float, and the total shares owned by insiders. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average.

Update Frequency: Daily

See Insiders Top Picks, which provides a list of companies with highest insider accumulation.

Officer Sentiment Score

The Officer Sentiment Score finds companies being bought by Corporate Officers.

By definition Corporate Officers are Corporate Insiders, but unlike some of the other Insiders (10% Shareholders and Board Members), Officers work for the company on a daily basis, and they user their own money when trading. (10% Shareholders and Board Members are often fund managers managing other people’s money.) As such, insider trades made by Officers are much more significant and should be treated appropriately.

Like the Insider Sentiment Score, the Officer Sentiment Score is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of officer accumulation.

Update Frequency: Daily

See Insiders Top Picks, which provides a list of companies with highest insider sentiment.

Key Insider Metrics

This card shows how the company ranks along various insider metrics. The percentile rank shows how this company compares to other companies in the US markets. Higher rankings are indicative of better situations.

For example, it is generally accepted that insider buying is a positive indicator, so companies with more insider buying would rank higher than companies with less insider buying (or even insider selling).

Net Number of Insiders Buying (Rank)

0 ( )

9607 out of 11305

Net Number of Insiders Buying is the total number of insiders buying minus the total number of insiders selling in the last 90 days. The percentile rank is shown here (range from 0 to 100%).

Percent of Float Bought by Insiders (Rank)

0.000 %( )

9522 out of 11224

Percent of Float Bought by Insiders is the total number of shares purchased by insiders minus the total number of shares sold by insiders in the last 90 days, divided by the total float and multiplied by 100.

Insider Trading Chart

Entia Biosciences, Inc. insider trades are shown in the following chart. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Insider Roster and Profitability Metrics

This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings. Additionally, when possible we provide the historical trade performance for the insider. The historical trade performance is a weighted average of the performance of actual open-market purchase transactions made by the insider. For more information on how this is calculated, watch this YouTube webinar.

See our leaderboard of most profitable insider traders.

Insider Avg Profit (%) Shares
Owned
Split
Adjusted
Andres Devin D. Chief Operating Officer - [O] 1,171,671 1,171,671
Capital Ltd Anka 10% Owner - [10%] 3,042,455 3,042,455
Delta Group Investments Ltd 10% Owner - [10%] 3,042,455 3,042,455
Insider Avg Profit (%) Shares
Owned
Split
Adjusted
Marvin S Md Hausman Chairman, CSTO, Director - [D] [O] 10,188,900 10,188,900
Carl J Johnson President and CEO, Director - [D] [O] 850,000 850,000
Philip A Sobol Director - [D] 281,667 281,667
Insider Avg Profit (%) Shares
Owned
Split
Adjusted
Elliot Shelton Secretary, Director - [D] [O] 976,250 976,250
Cheuk Ho Tam 10% Owner - [10%] 1,521,228 1,521,228
Timothy A Timmins EVP, COO and CFO - [O] 800,000 800,000
Wah On Edward Wong 10% Owner - [10%] 1,521,228 1,521,228

Report errors via our new Insider Auditing Tool

Track Records of Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ERGO / Entia Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical .

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2016-12-05 HAUSMAN MARVIN S MD 10,000.0000 10,000.0000 3 0.1400
2016-05-20 JOHNSON CARL J 0.1000 0.1000
2014-09-25 HAUSMAN MARVIN S MD 2,162,980 0.3000 2,162,980 0.3000 648,894
2014-09-25 ANDRES DEVIN D. 429,640 0.3000 429,640 0.3000 128,892

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ERGO / Entia Biosciences, Inc. Insider Trades
Track Records of Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ERGO / Entia Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical .

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ERGO / Entia Biosciences, Inc. Insider Trades
Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2017-02-16 2017-02-16 4 HAUSMAN MARVIN S MD ERGO Common Stock A - Award D 250,000 10,188,900
2017-02-16 2017-02-14 4 HAUSMAN MARVIN S MD ERGO Common Stock A - Award D 300,000 9,938,900
2017-02-16 2017-02-14 4 HAUSMAN MARVIN S MD ERGO Common Stock A - Award D 200,000 9,638,900
2017-02-16 2017-02-14 4 HAUSMAN MARVIN S MD ERGO Common Stock A - Award D 600,000 9,438,900
2017-02-16 2017-02-14 4 HAUSMAN MARVIN S MD ERGO Common Stock A - Award D 0.1750 1,861,170 326 8,838,900
2017-02-16 2017-02-14 4 Shelton Elliot ERGO Common Stock A - Award D 250,000 976,250
2017-02-16 2017-02-14 4 Shelton Elliot ERGO Common Stock A - Award D 200,000 726,250
2017-02-16 2017-02-16 4 TIMMINS TIMOTHY A ERGO Common Stock A - Award D 250,000 800,000
2017-02-16 2017-02-14 4 TIMMINS TIMOTHY A ERGO Common Stock A - Award D 300,000 550,000
2017-02-16 2017-02-14 4 TIMMINS TIMOTHY A ERGO Common Stock A - Award D 250,000 250,000
2017-02-16 2017-02-16 4 JOHNSON CARL J ERGO Common Stock A - Award D 250,000 850,000
2017-02-16 2017-02-14 4 JOHNSON CARL J ERGO Common Stock A - Award D 300,000 600,000
2017-02-16 2017-02-14 4 JOHNSON CARL J ERGO Common Stock A - Award D 300,000 600,000
2016-12-06 2016-12-05 4 HAUSMAN MARVIN S MD ERGO Warrant P - Purchase D 0.10 40,000 40,000
2016-12-06 2016-12-05 4 HAUSMAN MARVIN S MD ERGO 10% Convertible P - Purchase D 10,000.0000
2016-05-24 2016-05-20 4 JOHNSON CARL J ERGO Warrant P - Purchase D 0.12 0.1250 25,000 3 25,000
2016-05-24 2016-05-20 4 JOHNSON CARL J ERGO 8% Conv Debenture P - Purchase D 0.10 0.1000 250,000
2015-12-09 3 ANKA CAPITAL LTD By Delta Group Investments Limited ERGO Common Stock I 1,983,064
2015-12-09 3 ANKA CAPITAL LTD By Delta Group Investments Limited ERGO Common Stock I 1,983,064
2015-12-09 2015-05-08 4 TAM CHEUK HO By Delta Group Investments Limited ERGO Common Stock A - Award I 0.0100 1,025,462 10 1,521,228
2015-12-09 2015-05-08 4 WONG WAH ON EDWARD By Delta Group Investments Limited ERGO Common Stock A - Award I 0.0100 1,025,462 10 1,521,228
2015-12-09 2015-05-08 4 Delta Group Investments Ltd ERGO Common Stock A - Award D 0.0100 2,050,923 21 3,042,455
2015-12-09 2015-05-08 4 ANKA CAPITAL LTD By Delta Group Investments Limited ERGO Common Stock A - Award I 0.0100 2,050,923 21 3,042,455
2015-11-10 3 WONG WAH ON EDWARD Brender Services Limited ERGO Common Stock I 1,012,666
2015-11-10 3 WONG WAH ON EDWARD Brender Services Limited ERGO Common Stock I 1,012,666
2015-11-10 3 WONG WAH ON EDWARD Delta Group Investments Limited ERGO Common Stock I 1,249,982
2015-11-10 3 WONG WAH ON EDWARD Delta Group Investments Limited ERGO Common Stock I 1,249,982
2015-11-10 3 TAM CHEUK HO Delta Group Investments Limited ERGO Common Stock I 1,269,537
2015-11-10 3 TAM CHEUK HO Suncraft Limited ERGO Common Stock I 1,051,776
2015-11-10 3 TAM CHEUK HO Delta Group Investments Limited ERGO Common Stock I 1,269,537
2015-11-10 3 TAM CHEUK HO Suncraft Limited ERGO Common Stock I 1,051,776
2015-09-30 3 Delta Group Investments Ltd ERGO Common Stock D 1,983,064
2015-09-30 3 Delta Group Investments Ltd ERGO Common Stock D 1,983,064
2015-04-28 2015-04-24 4 HAUSMAN MARVIN S MD ERGO Common Stock A - Award D 0.2000 600,000 120 4,757,200
2015-04-28 2015-04-24 4 SOBOL PHILIP A ERGO Common Stock A - Award D 0.2000 200,000 40 281,667
2015-04-28 2015-04-24 4 Shelton Elliot ERGO Common Stock A - Award D 0.2000 200,000 40 326,250
2015-04-28 2015-04-24 4 ANDRES DEVIN D. ERGO Common Stock A - Award D 0.2000 550,000 110 1,171,671
2014-11-12 2014-09-25 4 HAUSMAN MARVIN S MD ERGO COMMON STOCK P - Purchase D 0.3000 2,162,980 649 4,171,825
2014-11-12 2014-06-30 4 SOBOL PHILIP A ERGO Common Stock Purchase Warrant P - Purchase D 0.30 0.3000 1 0 1
2014-11-12 2014-06-30 4 SOBOL PHILIP A ERGO Common Stock Purchase Warrant P - Purchase D 0.30 0.3000 15,000 4 15,000
2014-11-12 2014-09-25 4 ANDRES DEVIN D. ERGO COMMON STOCK P - Purchase D 0.3000 429,640 129 621,671
2014-11-05 2014-11-03 4 SOBOL PHILIP A ERGO Common Stock Purchase Warrant P - Purchase D 0.30 0.3000 15,000 4 15,000
2013-12-19 2013-12-17 4 HAUSMAN MARVIN S MD ERGO COMMON STOCK P - Purchase D 0.3800 62,505 24 2,482,488
2013-12-19 2013-12-17 4 SOBOL PHILIP A ERGO Promissory Note P - Purchase D 0.65 0.6500 1 0 1
2013-12-19 2013-12-17 4 SOBOL PHILIP A ERGO Common Stock Purchase Warrant P - Purchase D 0.65 0.6500 20,000 13 20,000
2013-12-19 2013-12-17 4 ANDRES DEVIN D. ERGO COMMON STOCK P - Purchase D 0.3800 52,089 20 201,031
2013-11-05 2013-11-04 4 HAUSMAN MARVIN S MD ERGO Common Stock Purchase Warrant A - Award D 1.00 1.0000 7,313 7 7,313
2013-11-05 2013-11-04 4 SOBOL PHILIP A ERGO Common Stock Purchase Warrant A - Award D 1.00 1.0000 99,669 100 9,669
2013-10-17 2013-07-11 4 HAUSMAN MARVIN S MD ERGO Incentive Stock Options A - Award D 0.45 0.4500 200,000 90 200,000
2013-10-17 2013-07-11 4 HAUSMAN MARVIN S MD ERGO Common Stock Purchase Warrant A - Award D 0.45 0.4500 400,000 180 400,000
2013-10-17 2013-07-11 4 SOBOL PHILIP A ERGO Common Stock Purchase Warrant A - Award D 0.45 0.4500 150,000 68 150,000
2013-10-17 2013-07-11 4 Shelton Elliot ERGO Common Stock Purchase Warrant A - Award D 0.45 0.4500 150,000 68 150,000
2013-10-17 2013-07-11 4 ANDRES DEVIN D. ERGO Common Stock Purchase Warrant A - Award D 0.45 0.4500 150,000 68 150,000
2013-10-17 2013-07-11 4 ANDRES DEVIN D. ERGO Incentive Stock Options A - Award D 0.45 0.4500 150,000 68 150,000
2013-07-22 2013-07-12 4 HAUSMAN MARVIN S MD ERGO COMMON STOCK P - Purchase D 0.3800 131,579 50 2,419,981
2013-06-13 2013-06-11 4 SOBOL PHILIP A ERGO Common Stock Purchase Warrants P - Purchase D 0.45 0.4500 10,000 4 10,000
2013-06-13 2013-06-11 4 SOBOL PHILIP A ERGO Convertible Promissory Note P - Purchase D 5.00 40,000.0000 1 40 25,000
2013-06-13 2013-06-11 4 SOBOL PHILIP A Philip & Debra Sobol Trust ERGO Series A Preferred Stock P - Purchase I 0.50 5.0000 11,338 57 19,338
2013-06-12 2013-06-11 4 HAUSMAN MARVIN S MD ERGO Series A Preferred Stock P - Purchase D 0.50 80,125.0000 16,025 1,284,003 21,025
2013-06-12 2012-05-30 4 HAUSMAN MARVIN S MD ERGO Series A Preferred Stock P - Purchase D 0.50 5.0000 1,000 5 5,000
2013-06-12 2013-06-11 4 ANDRES DEVIN D. ERGO Common Stock P - Purchase D 0.3800 131,579 50 148,942
2013-02-22 2013-02-20 4 ANDRES DEVIN D. ERGO Non-Statutory Stock Option A - Award D 0.38 0.3800 25,000 10 25,000
2013-01-22 2013-01-17 4 HAUSMAN MARVIN S MD ERGO Series A Preferred Stock A - Award D 0.50 5.0000 1,000 5 4,000
2012-06-19 2012-05-18 4 SOBOL PHILIP A ERGO Convertible Promissory Note A - Award D 5.00 25,000.0000 1 25 1
2012-06-19 2012-05-18 4 SOBOL PHILIP A Philip & Debra Sobol Trust ERGO Common Stock Purchase Warrant A - Award I 0.55 150,000 150,000
2012-06-19 2012-05-18 4 SOBOL PHILIP A Philip & Debra Sobol Trust ERGO Series A Preferred Stock A - Award I 0.50 5.0000 5,000 25 5,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista